Fundz

Addition Therapeutics raises $100M in Funding, led by investors SR One, Pivotal Life Sciences, and others to expand operations and R&D efforts.

PRIVATEDec 18, 2025

Amount Raised

$100 Million

Round Type

Funding Round

San FranciscoBiotechnologyHealth Care

Investors

Pivotal Life SciencesAbingworthOsage University PartnersGates FoundationBevcSR One

Description

Addition Therapeutics, a San Francisco-based genomic medicine company, raised $100M in funding. The company intends to use the funds to expand operations and its R&D efforts. Backers included SR One, Pivotal Life Sciences, Abingworth, Osage University Partners, the Gates Foundation, and BEVC. The leadership team, led by CEO Ron Park, is developing therapeutics for chronic and rare diseases.

Who else raised in Biotechnology and Health Care around the same time

Companies in the same sectors as Addition Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • ORamaVR raised $4.5M (Seed) on January 30, 2026.
  • CytoDyn raised $19M on January 30, 2026.
  • Richtech Robotics raised $39M (Post-IPO Equity) on January 29, 2026.
  • Biopeak raised $2.7M (Seed) on January 29, 2026.
  • Tenpoint Therapeutics raised $235M (Series B) on January 29, 2026.
  • PranaX raised $17M (Series A) on January 29, 2026.

Who to call at Addition Therapeutics, and when

A new round usually means Addition Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Addition Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Addition Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Addition Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Addition Therapeutics

Location

San Francisco, California, United States

About

Addition Therapeutics is a San Francisco-based genomic medicine company developing an all-RNA, non-viral, LNP-based PRINT platform. The company is focused on advancing a pipeline of PRINTed therapeutics for chronic and rare diseases. It is a spin-out of Professor Kathleen Collins’ laboratory at the University of California. Addition Therapeutics aims to use its funding to expand operations and research efforts.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Addition Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsRonald P., CEO, Board Director hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Addition Therapeutics's next move

See what Strategic adds

Addition Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.